biostudies-literatureUnknown43(14)Tardif JCAkcea Therapeutics<h4>Aims</h4>Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.<h4>Methods and results</h4>A randomized, double-blind, placebo-controlled, dose-ranging study was conducted in 114 patients with fasting serum triglycerides 200-500 mg/dL (2.26-5.65 mmol/L). Patients received olezarsen (10 or 50 mg every 4 weeks, 15 mg every 2 weeks, or 10 mg every week) or saline placebo subcutaneously for 6-12 months. The primary endpoint was the percent change in fasting triglyceride levEuropean heart journal1401-1412https://www.ebi.ac.uk/biostudies/studies/S-EPMC8986458biostudies-literatureApolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.PMC8986458Baum SJBartlett VJBallantyne CMAlexander VJHurh EAmour ESKingsbury JKarwatowska-Prokopczuk ETami JWitztum JLTsimikas STardif JCFigueroa ALShapiro MDMoriarty PMGeary RSGaudet DO'Dea LSLfalseApolipoprotein C-III reduction in subjects with moderate hypertriglyceridaemia and at high cardiovascular risk.<h4>Aims</h4>Hypertriglyceridaemia is associated with increased risk of cardiovascular events. This clinical trial evaluated olezarsen, an N-acetyl-galactosamine-conjugated antisense oligonucleotide targeted to hepatic APOC3 mRNA to inhibit apolipoprotein C-III (apoC-III) production, in lowering triglyceride levels in patients at high risk for or with established cardiovascular disease.<h4>Methods and results</h4>A randomized, double-blind, placebo-controlled, dose-ranging study was conducted in 114 patients with fasting serum triglycerides 200-500 mg/dL (2.26-5.65 mmol/L). Patients received olezarsen (10 or 50 mg every 4 weeks, 15 mg every 2 weeks, or 10 mg every week) or saline placebo subcutaneously for 6-12 months. The primary endpoint was the percent change in fasting triglyceride lev2022-01-01T00:00:00Z2022 Apr2026-06-07T03:21:00.338Z2024-10-18T03:20:07.896ZS-EPMC89864583502599310.1093/eurheartj/ehab820